Christopher Brooks
- Oncology top 0.5%
- CAR-T cell therapy research 28
- Cancer-related Molecular Pathways 18
- Geriatrics and Gerontology top 0.5%
- Molecular Biology top 2%
- Ubiquitin and proteasome pathways 12
- Dermatology top 1%
- Cutaneous lymphoproliferative disorders research 14
- Cancer Research top 2%
-
- Toxin Mechanisms and Immunotoxins 19
-
- Myeloproliferative Neoplasms: Diagnosis and Treatment 11
- Chronic Lymphocytic Leukemia Research 10
-
- Multiple Myeloma Research and Treatments 10
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Christopher Brooks
83 papers receiving 5.2k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 2.9k
- Geriatrics and Gerontology 387
- Molecular Biology 3.6k
- Dermatology 408
- Cancer Research 671
Countries citing papers authored by Christopher Brooks
This map shows the geographic impact of Christopher Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Brooks more than expected).
Fields of papers citing papers by Christopher Brooks
This network shows the impact of papers produced by Christopher Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Brooks. The network helps show where Christopher Brooks may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christopher Brooks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2021 | 14 | |
| 3 | 2021 | 27 | |
| 4 | 2020 | 3 | |
| 5 | 2019 | 57 | |
| 6 | 2018 | 33 | |
| 7 | 2015 | 1 | |
| 8 | 2011 | 231 | |
| 9 | 2011 | 157 | |
| 10 | 2010 | 86 | |
| 11 | 2009 | 149 | |
| 12 | 2009 | 7 | |
| 13 | 2008 | 359 | |
| 14 | 2007 | 64 | |
| 15 | 2007 | 35 | |
| 16 | 2007 | 119 | |
| 17 | p53 Ubiquitination: Mdm2 and Beyondbreakdown → | 2006 | 713 |
| 18 | 2004 | 43 | |
| 19 | A Dynamic Role of HAUSP in the p53-Mdm2 Pathwaybreakdown → | 2004 | 527 |
| 20 | Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulationbreakdown → | 2003 | 620 |
About Christopher Brooks
Christopher Brooks is a scholar working on Hematology, Genetics, Oncology, Immunology and Dermatology, having authored 85 papers that have together received 5.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (28 papers), Toxin Mechanisms and Immunotoxins (19 papers), Cancer-related Molecular Pathways (18 papers), Cutaneous lymphoproliferative disorders research (14 papers), Ubiquitin and proteasome pathways (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Multiple Myeloma Research and Treatments (10 papers). The work is most often cited by research in Oncology (2.9k citations), Geriatrics and Gerontology (387 citations), Molecular Biology (3.6k citations), Dermatology (408 citations) and Cancer Research (671 citations). Christopher Brooks has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Wei Gu, Muyang Li, Wei Gu, Ning Kon, Jianyuan Luo, Delin Chen, Richard Baer, Foon Wu-Baer, M Li and Naveen Pemmaraju. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Leukemia and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.